In a post‐hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT), either a high level of serum NT‐proBNP at baseline or a 25% increase in NT‐proBNP level after 1 year was significantly associated with a ≥30% decline in eGFR. The gene discussed is NPPB; the disease is blood pressure trait.